NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

Phase 4 Completed 513 enrolled Novo Nordisk A/S

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.

Timeline

Start: 2004-07
Primary completion: 2005-03
Completion: 2005-03

Publications

Results Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB; CONTROL Study Group. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2008 Feb;10(1):1-10. doi: 10.1089/dia.2007.0234.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin aspart	Protein / enzyme biologic	—	Subcutaneous

NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications